by rss feed | Dec 16, 2025 | Celularity FDA warning, FDA Warning Letter, News Feeds
Three recent FDA warning letters, including one issued to publicly-traded Celularity, paint a helpful picture of where FDA oversight stands. They illustrate how the FDA’s classification of placental/amniotic products greatly depends on how a firm positions a product...
